Multiple Myeloma: all 3,712 studies

Page 12 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaCompletedNCT02076009Phase 3Results posted
• Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT02075021Phase 1/2Results posted
• Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916CompletedNCT02064387Phase 1Results posted
• MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple MyelomaCompletedNCT02057640Phase 1/2Results posted
• Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple MyelomaCompletedNCT02046070Phase 2Results posted
• Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple MyelomaTerminatedNCT02043860Phase 1Results posted
• TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)CompletedNCT02043847Phase 1Results posted
• Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell DyscrasiasCompletedNCT02041325Phase 2Results posted
• Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
• A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)TerminatedNCT02036502Phase 1Results posted
• Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line TherapyTerminatedNCT02020941Phase 2Results posted
• Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02011113Phase 2Results posted
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaActive, not recruitingNCT02004275Phase 1/2Results posted
• Meloxicam vs Placebo for MobilizationCompletedNCT02003625Phase 2Results posted
• Carfilzomib With Bendamustine and Dexamethasone in Multiple MyelomaTerminatedNCT02002598Phase 1/2Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaTerminatedNCT01997840Phase 1/2Results posted
• CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell TransplantationCompletedNCT01995708Phase 1Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01989598Phase 2Results posted
• An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiDCompletedNCT01985126Phase 2Results posted
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01980589Phase 1Results posted
• Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref MyelomaTerminatedNCT01979276Phase 1/2Results posted
• Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple MyelomaTerminatedNCT01969565Phase 2Results posted
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple MyelomaTerminatedNCT01965834Phase 2Results posted
• Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
• SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01955434Phase 2Results posted
• A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)CompletedNCT01953692Phase 1Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal DiseaseCompletedNCT01949532Phase 1Results posted
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2Results posted
• Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01946152Phase 1/2Results posted
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
• Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
• Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid MalignanciesCompletedNCT01919619Phase 2Results posted
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple MyelomaCompletedNCT01919086Phase 2Results posted
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaCompletedNCT01903811Phase 2Results posted
• Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01899326Not applicableResults posted
• Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsTerminatedNCT01897714Phase 1/2Results posted
• CT Antigen TCR-Engineered T Cells for MyelomaTerminatedNCT01892293Phase 1/2Results posted
• PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedNCT01891643Phase 3Results posted
• Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT01889420Phase 1Results posted
• UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple MyelomaCompletedNCT01884688Phase 2Results posted
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaTerminatedNCT01881789Phase 1/2Results posted
• Cabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaCompletedNCT01866293Phase 1/2Results posted
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisCompletedNCT01864018Phase 1/2Results posted
• Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk MyelomaCompletedNCT01858558Phase 2Results posted
• A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple MyelomaCompletedNCT01852799Phase 2Results posted
• Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous TransplantCompletedNCT01852591Not applicableResults posted
• IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01850524Phase 3Results posted
• Study of SyB L-0501 to Treat Relapsed/Refractory Multiple MyelomaCompletedNCT01849848Phase 2Results posted
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaCompletedNCT01849783Phase 2Results posted
• Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01842308Phase 1/2Results posted
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT01832727Phase 1/2Results posted
• Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal ImpairmentCompletedNCT01830816Phase 1Results posted
• WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationCompletedNCT01827137Phase 1/2Results posted
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Phase 3Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01816971Phase 2Results posted
• A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)CompletedNCT01804140Results posted
• A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple MyelomaCompletedNCT01801436Phase 3Results posted
• Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma RelapseTerminatedNCT01794572Not applicableResults posted
• Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT01794520Phase 1/2Results posted
• Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideCompletedNCT01794039Phase 2Results posted
• Intervention for Symptom Burden During Maintenance Therapy for Multiple MyelomaCompletedNCT01793051Phase 2Results posted
• Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving BortezomibTerminatedNCT01783522Phase 2Results posted
• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)CompletedNCT01782963Phase 2Results posted
• Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose CarfilzomibCompletedNCT01775553Phase 2Results posted
• Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic AcidTerminatedNCT01772719Not applicableResults posted
• Unrelated Umbilical Cord Blood (UBC)TransplantationCompletedNCT01768845Not applicableResults posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedNCT01755975Phase 1/2Results posted
• Bendamustine + Pomalidomide + Dex in R/R Multiple MyelomaActive, not recruitingNCT01754402Phase 1/2Results posted
• Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple MyelomaCompletedNCT01745588Phase 2Results posted
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01734928Phase 3Results posted
• Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple MyelomaCompletedNCT01731886Phase 4Results posted
• Velcade + Cyclophosphamide in Newly Diagnosed Multiple MyelomaTerminatedNCT01729338Phase 2Results posted
• Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01729091Phase 2Results posted
• Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma PatientsTerminatedNCT01720043Phase 2Results posted
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01718743Phase 2Results posted
• A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)CompletedNCT01713582Phase 1Results posted
• Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01712789Phase 3Results posted
• Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell TransplantCompletedNCT01706666Phase 2Results posted
• A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01698801Phase 2Results posted
• Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing RegimensTerminatedNCT01695330Phase 2Results posted
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationCompletedNCT01690143Phase 1/2Results posted
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaCompletedNCT01677858Phase 1/2Results posted
• Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyTerminatedNCT01676961Phase 2Results posted
• Lenalidomide Maintenance Therapy for Multiple MyelomaTerminatedNCT01675141Phase 2Results posted
• A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple MyelomaTerminatedNCT01672736Phase 1/2Results posted
• QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01670994Phase 1/2Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell TransplantationTerminatedNCT01653418Phase 2Results posted
• Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)CompletedNCT01651039Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01646762Phase 2Results posted
• Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01645930Phase 1Results posted
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCompletedNCT01632150Phase 2Results posted
• UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple MyelomaCompletedNCT01621672Phase 3Results posted
• Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple MyelomaCompletedNCT01615029Phase 1/2Results posted
• Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01605032Phase 2Results posted

← Multiple Myeloma overview